Liz KaneImpactful Strategy
Bud BilanichSuccess Coach
Brenda SnowAuthentic Patient Voice
Matthew DurhamOmnidynamic Marketing
Joey CohenMedication Adherence
Frank BurrellScientific Storytelling
Pat PurcellMeeting Engagement
Daniel SontupeMarket Access
Stacey GandlerBrand Nourishment
Amy GilesIncreasing Engagement
Matt TurnerPatient Affordability
Paul TheisenPatient Acquisition
David LinetskyPoint-of-Care Marketing
Suma Ramadas, PhDMedical Affairs
Encouraging results evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®) ...
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes ...
Username
Email
Password
Confirm Password
Remember Me
Username or Email